Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EXEL | Common Stock | Options Exercise | $884K | +60K | +10.5% | $14.74 | 632K | Aug 3, 2023 | Direct | F1 |
transaction | EXEL | Common Stock | Sale | -$1.23M | -60K | -9.5% | $20.51 | 572K | Aug 3, 2023 | Direct | F1, F2 |
transaction | EXEL | Common Stock | Options Exercise | $884K | +60K | +10.5% | $14.74 | 632K | Aug 4, 2023 | Direct | F1 |
transaction | EXEL | Common Stock | Sale | -$1.24M | -60K | -9.5% | $20.68 | 572K | Aug 4, 2023 | Direct | F1 |
holding | EXEL | Common Stock | 2.72K | Aug 3, 2023 | By 401(k) | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EXEL | Option (right to buy) | Options Exercise | $0 | -60K | -50% | $0.00 | 60K | Aug 3, 2023 | Common Stock | 60K | $14.74 | Direct | F4 |
transaction | EXEL | Option (right to buy) | Options Exercise | $0 | -60K | -100% | $0.00* | 0 | Aug 4, 2023 | Common Stock | 60K | $14.74 | Direct |
Id | Content |
---|---|
F1 | Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
F2 | Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.50 to $20.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
F3 | Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 2, 2023. |
F4 | The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. |